Bausch + Lomb在购买商谈失败后不会出售,导致其库存下降8.45%。 Bausch + Lomb won't sell, after purchase talks fell short, causing its stock to drop 8.45%.

Bausch + Lomb, 一家眼科保健公司,在与潜在买方交谈未能达到该公司的估值预期后,不会出售。 Bausch + Lomb, an eye health company, will not be sold after talks with a potential buyer failed to meet the company's valuation expectations. 该公司88%由Bausch健康公司拥有,将继续独立经营,并于2月19日报告其2024年的收入和2025年的指导意见。 The company, owned 88% by Bausch Health Companies Inc., will continue its independent operations and report its 2024 earnings and 2025 guidance on February 19. 其库存在宣布后下降了8.45%至16.19美元,分析师给予它“稳住”评级,平均价格目标为20.25美元。 Its stock fell 8.45% to $16.19 after the announcement, with analysts giving it a "Hold" rating and an average price target of $20.25.